Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)

Sumitomo Pharma

12/08/2026 24:37

Aug 12 (Reuters) - Sumitomo Pharma Co Ltd 4506.T:
SUMITOMO PHARMA CO LTD: REGARDING A REPORT CONCERNING SUMITOMO PHARMA ( COMPANY'S VIEWS ON GCR AUGUST 7 REPORT)
SUMITOMO PHARMA CO LTD: AUGUST 7 REPORT IS BASED ON GOTHAM CITY RESEARCH'S UNILATERAL VIEWS AND ASSERTIONS, WHICH ARE NOT ACCEPTABLE
SUMITOMO PHARMA CO LTD: COMPANY HAS CONFIRMED RELIABILITY OF MATERIALS SUBMITTED FOR REGULATORY REVIEW OF AMCHEPRY, AND AMCHEPRY WAS GRANTED CONDITIONAL AND TIME-LIMITED APPROVAL FOLLOWING SCIENTIFIC AND MEDICAL REVIEW AND ASSESSMENT BY RELEVANT REGULATORY AUTHORITIES
SUMITOMO PHARMA CO LTD: COMPANY IS APPROPRIATELY CONDUCTING A POST-MARKETING CLINICAL STUDY (PHASE 4 STUDY) AND STEADILY ACCUMULATING FURTHER EVIDENCE REGARDING EFFICACY AND SAFETY OF AMCHEPRY, WITH AIM OF OBTAINING FULL APPROVAL AS EARLY AS POSSIBLE
SUMITOMO PHARMA CO LTD: GCR PUBLISHED A REPORT ON AUGUST 3, 2026, CONTAINING UNILATERAL VIEWS REGARDING COMPANY'S FINANCIAL REPORTING
SUMITOMO PHARMA CO LTD: COMPANY WILL TAKE APPROPRIATE ACTION, INCLUDING LEGAL ACTION WHERE NECESSARY, IN RESPONSE TO INACCURATE OR MISLEADING INFORMATION IN ORDER TO PROTECT INTERESTS OF COMPANY AND ITS SHAREHOLDERS AND INVESTORS
Source text: ID:nTStk7e50f
Further company coverage: 4506.T

 (Reporting by Tokyo Newsroom)
 ((+81345201189;))